BioSpace News Archive

Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial in refractory patients demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented on June 5, at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 3-7, 2022.

LumiraDx Limited announced it has expanded its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism in symptomatic patients.

The global market for gingivitis diagnostics and therapeutics is expected to witness growth at a significant rate in the next few years owing to factors such as the rising number of smokers, women of reproductive age, and obese people across the globe.

Albany NY, United States: Cognitive disorders, also known as neurocognitive disorders, are defined as any disorder that significantly impairs the cognitive function of an individual.

Nordic Nanovector ASA provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin® in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma.

SprintRay is thrilled to announce SprintRay Crown™ by BEGO, a 3D printing resin poised to help improve the quality of restorative care in digital dentistry.

Insulet Corporation announced that management will present at the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on Wednesday, June 8, 2022, at 9:00 a.m..

BIOLASE, Inc., the global leader in dental lasers, announced that it will be presenting at the 2022 LD Micro Invitational, a prominent three-day investor conference, at the Four Seasons Hotel Westlake Village on Wednesday, June 8, 2022 at 3:30 PM PST / 6:30 PM EST.

Vaxxinity, Inc. announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the Jefferies Healthcare Conference, being held in New York, NY on Thursday, June 9, 2022 at 11:30 a.m. ET.

LAVA Therapeutics N.V. announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY.